Biotech Values

[ghmm]

FGEN:

While one can never be certain with Biotechs I don't see it as likely:
1-Their 50/50 share of Roxadustat development with AZ will stop (except in China) once they reach $116.5 million. At end of Q1 they indicated $52.1 million remained so probably next quarter sometime their obligation will be reached.
2-They just received a 120 million milestone from AZ (in addition to 15 million a quarter earlier)
3-If they decide to partner 3019 I would expect a pretty substantial up-front but this remains a big if on when/if they do so.

From the PR after the 120M

"FibroGen expects to have approximately $410 million to $415 million of cash, cash equivalents, investments, and receivables on June 30, 2015 "